Intelligent Bio Solutions (NASDAQ:INBS) and Cytosorbents (NASDAQ:CTSO) Critical Review

Intelligent Bio Solutions (NASDAQ:INBS) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Valuation and Earnings

This table compares Intelligent Bio Solutions and Cytosorbents”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22 million	1.59	-$12.43 million	($6.38)	-0.32
Cytosorbents	$37.06 million	0.48	-$8.20 million	($5.80)	-0.98

Cytosorbents has higher revenue and earnings than Intelligent Bio Solutions. Cytosorbents is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 2.8% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 7.8% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Intelligent Bio Solutions and Cytosorbents, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1	1	0	0	1.50
Cytosorbents	1	1	2	0	2.25

Cytosorbents has a consensus target price of $74.83, indicating a potential upside of 1,219.81%. Given Cytosorbents’ stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Intelligent Bio Solutions.

Risk & Volatility

Intelligent Bio Solutions has a beta of 4.48, meaning that its share price is 348% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Profitability

This table compares Intelligent Bio Solutions and Cytosorbents’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-269.28%	-145.68%	-81.70%
Cytosorbents	-48.94%	-431.65%	-41.94%

Summary

Cytosorbents beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a life sciences company focused on developing and commercializing non-invasive diagnostic and screening technologies. Its primary product is the Intelligent Bio Solutions Drug Screening System, a portable platform designed to detect drugs of abuse through sweat collected from a person’s fingerprint. The system uses a disposable drug screening cartridge and a handheld reader to analyze fingerprint sweat and provide results rapidly. The company markets the technology for applications such as workplace testing, law enforcement, rehabilitation programs, and other settings that require convenient, observed drug screening.

About Cytosorbents

CytoSorbents Corporation is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment. The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications.